Literature DB >> 24038906

Effect of Spilanthes acmella hydroethanolic extract activity on tumour cell actin cytoskeleton.

Cristina Pacheco Soares, Valeria Rosseto Lemos, Ary Gomes da Silva, Renan Meyer Campoy, Carlos Augusto Priante da Silva, Renato Farina Menegon, Iuri Rojahn, Walderez Moreira Joaquim.   

Abstract

Numerous natural products have pharmacological activity such that many biologically active compounds have led to the development of cancer chemotherapy drugs. Spilanthes acmella (Asteraceae) is widely cultivated in the State of Pará, Brazil, being employed in folk medicine for its anti-inflammatory, antimicrobial, antioxidant, analgesic, insecticide, and larvicidal properties. However, its cytotoxicity and influence on actin cytoskeleton organisation in tumour cell lines are practically nonexistent. We have verified the cytotoxicity of a hydroethanolic extract of the inflorescence of S. acmella, and examined its effects on the cytoskeleton of tumour cells. Decreasing concentrations of the extract (250, 500 and 1,000 µg/mL) were given to cultures of neoplastic cells (HEp-2). Cytotoxicity was assessed by the MTT test, and the influence on cytoskeleton organisation was examined by fluorescence microscopy. The IC50 of the hydroethanolic extract was 513 µg/mL, confirming the data obtained from the MTT assay that gave high cytotoxicity. The actin cytoskeleton arrangement of HEp2 cells at 500 and 1,000 µg/mL showed depolymerisation of the filaments, causing loss of morphology and consequently compromising cell adhesion.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24038906     DOI: 10.1002/cbin.10180

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  1 in total

1.  Acmella oleracea and Achyrocline satureioides as Sources of Natural Products in Topical Wound Care.

Authors:  Lais Thiemi Yamane; Eneida de Paula; Michelle Pedroza Jorge; Verônica Santana de Freitas-Blanco; Ílio Montanari Junior; Glyn Mara Figueira; Luís Adriano Anholeto; Patricia Rosa de Oliveira; Rodney Alexandre Ferreira Rodrigues
Journal:  Evid Based Complement Alternat Med       Date:  2016-09-29       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.